Vaccination against delta-Retroviruses: The Bovine Leukemia Virus Paradigm.

G. Gutierrez, S. M. Rodriguez, Alix de Brogniez, N. Gillet, R. Golime, Arsène Burny, J.-P. Jaworski, I. Alvarez, L. Vagnoni, K. Trono, L. Willems

Research output: Contribution to journalArticlepeer-review


[en] Bovine leukemia virus (BLV) and human T-lymphotropic virus type 1 (HTLV-1) are closely related d-retroviruses that induce hematological diseases. HTLV-1 infects about 15 million people worldwide, mainly in subtropical areas. HTLV-1 induces a wide spectrum of diseases (e.g., HTLV-associated myelopathy/tropical spastic paraparesis) and leukemia/lymphoma (adult T-cell leukemia). Bovine leukemia virus is a major pathogen of cattle, causing important economic losses due to a reduction in production, export limitations and lymphoma-associated death. In the absence of satisfactory treatment for these diseases and besides the prevention of transmission, the best option to reduce the prevalence of d-retroviruses is vaccination. Here, we provide an overview of the different vaccination strategies in the BLV model and outline key parameters required for vaccine efficacy.
Original languageEnglish
Pages (from-to)2416-2427
Number of pages12
Issue number6
Publication statusPublished - 2014
Externally publishedYes


  • Sciences de la santé humaine => Immunologie maladie infectieuse


Dive into the research topics of 'Vaccination against delta-Retroviruses: The Bovine Leukemia Virus Paradigm.'. Together they form a unique fingerprint.

Cite this